We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

418 hedge funds and large institutions have $14.8B invested in BioMarin Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 160 increasing their positions, 133 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 47

20% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 133

6% more capital invested

Capital invested by funds: $14B → $14.8B (+$809M)

9% more call options, than puts

Call options by funds: $82.3M | Put options by funds: $75.7M

1% more funds holding

Funds holding: 414 → 418 (+4)

0.69% less ownership

Funds ownership: 98.49% → 97.8% (-0.69%)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

Holders
418
Holders Change
+4
Holders Change %
+0.97%
% of All Funds
10.41%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.22%
New
62
Increased
160
Reduced
133
Closed
47
Calls
$82.3M
Puts
$75.7M
Net Calls
+$6.61M
Net Calls Change
+$11.7M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$971M
2
Primecap Management
Primecap Management
California
+$73.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$72.3M
4
Jennison Associates
Jennison Associates
New York
+$56.1M
5
ClearBridge Investments
ClearBridge Investments
New York
+$46M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$91.7M
2
HM
HealthCor Management
New York
-$64.2M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$46.5M
4
Victory Capital Management
Victory Capital Management
Texas
-$44.4M
5
Marshall Wace
Marshall Wace
United Kingdom
-$37M
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
326
Family Management
New York
$263K – – –
PAA
327
Peregrine Asset Advisers
Oregon
$263K – – –
SGS
328
Sterling Global Strategies
California
$263K – – –
D.E. Shaw & Co
329
D.E. Shaw & Co
New York
$263K +$267K +3,000 New
Millennium Management
330
Millennium Management
New York
$261K +$265K +2,977 New
Simplex Trading
331
Simplex Trading
Illinois
$252K -$1.14M -12,771 -82%
SB
332
Suntrust Banks
Georgia
$251K +$254K +2,855 New
Caisse de Depot et Placement du Quebec (CDPQ)
333
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$246K -$907K -10,200 -78%
OA
334
Opes Advisors
California
$243K +$246K +2,766 New
GAM
335
Gemmer Asset Management
California
$241K -$142K -1,600 -37%
LTFS
336
Ladenburg Thalmann Financial Services
Florida
$239K +$12.4K +139 +5%
B
337
BancorpSouth
Mississippi
$237K – – –
Nomura Holdings
338
Nomura Holdings
Japan
$237K +$240K +2,702 New
ACM
339
Advent Capital Management
New York
$232K +$235K +2,640 New
Envestnet Asset Management
340
Envestnet Asset Management
Illinois
$227K -$22K -247 -9%
Verition Fund Management
341
Verition Fund Management
Connecticut
$226K +$229K +2,577 New
AIM
342
Achmea Investment Management
Netherlands
$224K +$227K +2,554 New
IRF
343
IBM Retirement Fund
New York
$223K -$1.26M -14,137 -88%
HCMT
344
Highland Capital Management (Texas)
Texas
$215K -$1.59M -17,839 -88%
FAAS
345
First Allied Advisory Services
California
$212K -$9.07K -102 -4%
DWA
346
Douglass Winthrop Advisors
New York
$206K -$67.6K -760 -24%
CI
347
Cigna Investments
Connecticut
$205K +$208K +2,341 New
LOAME
348
Lombard Odier Asset Management (Europe)
United Kingdom
$203K +$206K +2,313 New
DCM
349
Dupont Capital Management
Delaware
$200K – – –
HHMI
350
Howard Hughes Medical Institute
Maryland
$200K +$129K +1,451 +175%
12 13
14
15 16

BMRN Hedge Fund Activity: Q1 2017 in Review

418 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2017, worth a combined $14.8B — up 5.8% from $14B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new BMRN positions and 47 closed out — a net gain of 15 holders — while 160 added to existing stakes and 133 trimmed.

The largest buyer was BlackRock, adding an estimated $971M. The largest seller was JP Morgan Chase, cutting an estimated $91.7M.

  • 418 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2017, up from 414 in Q4 2016.
  • Funds reported $14.8B of BioMarin Pharmaceuticals stock for Q1 2017, up 5.8% quarter-over-quarter.
  • 62 funds opened new BioMarin Pharmaceuticals positions in Q1 2017 and 47 closed out, a net change of +15 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $971M added.
  • The largest BioMarin Pharmaceuticals seller in Q1 2017 was JP Morgan Chase, an estimated $91.7M sold.

Based on aggregated 13F filings for Q1 2017.